Peptilogics receives FDA fast track designation for PLG0206, an investigational peptide therapeutic in development for the treatment of peri-prosthetic joint infection

Peptilogics

19 July 2022 - PLG0206 has the potential to be the first approved therapy specifically indicated for the treatment of peri-prosthetic joint infection.

Peptilogics today announced that the U.S. FDA has granted fast track designation to the company’s lead drug candidate, PLG0206, for the treatment of peri-prosthetic joint infection.

Read Peptilogics press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Fast track